Skip to content

A clinical trial to know the effect and safety of Exocool Pain Numbing Device on pain due to vaccination and intravenous cannulation in children

A Randomized, Controlled, Two-arm, Parallel, Sham-controlled clinical study to assess the performance and safety of Exocool Pain Numbing Device on pain due to vaccination and intravenous cannulation in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041967
Enrollment
60
Registered
2022-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Exocool Pain Numbing Device: Exocool Pain Numbing Device to be used numb an area on the body while administering injection It takes about 4-6 seconds to numb sensitive skin and 8-10 sec

Sponsors

Camex Wellness Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Children age 4-18years 2 Subjects requires single immunization such as MMR 3 Subjects prescribed one or more category of drug for injection or cannulation. 4Subject is willing to provide the informed consent 5 Subject having not participated in a similar investigation in the past one month. 6 Subjects ready to follow instructions during the study period.

Exclusion criteria

Exclusion criteria: 1 Subjects skin is too resistant 2 Incomplete information of patients. 3 Subject having any allergic reaction to metal and cold sensation. 4 Confirmed needle phobia. 5 Child with haemophillia or bleeding disorder 6 Eczema/skin damage at injection site 7 Children with behavioural/developmental disorder

Design outcomes

Primary

MeasureTime frame
To assess the Pain using the VAS scale by patient and carerTimepoint: Day1, Day2 and Day7

Secondary

MeasureTime frame
Success or failure of the injection in the presence of complications, Satisfaction scores using Likert scale and whether they would use the device again will be assessedTimepoint: Day1, Day2 and Day7;To assess child WONG Baker Faces Scale scoreTimepoint: Day 1;To assess the adverse events immediate or delayed pain, erythema, sustained blanching, urticaria and pruritus in a 4 point scaleTimepoint: Day1, Day2 and Day7

Countries

India

Contacts

Public ContactRahul Chopra

Pharexcel Consulting Private Limited

info@pharexcelconsulting.com09878551428

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026